Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:00 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Peripheral T-Cell Lymphoma, Not Otherwise Specified Clear all
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma, HTLV-1 Infection, NK-Cell Lymphoma, Unclassifiable, Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Mycosis Fungoides, Refractory Adult T-Cell Leukemia/Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Nasal Type Extranodal NK/T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Laboratory Biomarker Analysis, Nivolumab
Other · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced May 21, 2026, 5:00 PM EDT
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Nasal Type Extranodal NK/T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous Anaplastic Large Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Small Lymphocytic Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions
Cholecalciferol, Laboratory Biomarker Analysis
Dietary Supplement · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
565 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
5
States / cities
Scottsdale, Arizona • Atlanta, Georgia • Iowa City, Iowa + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced May 21, 2026, 5:00 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Adult Nasal Type Extranodal NK/T-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, B Lymphoblastic Leukemia/Lymphoma, Blastic Plasmacytoid Dendritic Cell Neoplasm, Burkitt Leukemia, Central Nervous System Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3 Follicular Lymphoma, Hepatosplenic T-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Mycosis Fungoides, Nasal Type Extranodal NK/T-Cell Lymphoma, Nodal Marginal Zone Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Effusion Lymphoma, Sezary Syndrome, Splenic Marginal Zone Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Systemic Anaplastic Large Cell Lymphoma, T Lymphoblastic Leukemia/Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Questionnaire Administration, Salvia hispanica Seed
Other · Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 14, 2019 · Synced May 21, 2026, 5:00 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Systemic Anaplastic Large Cell Lymphoma, Lymphoma, T-Cell, Peripheral, Lymphoma, T-Cell
Interventions
Soquelitinib, Belinostat, Pralatrexate
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
21
States / cities
Duarte, California • Irvine, California • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced May 21, 2026, 5:00 PM EDT
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Follicular Helper T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Duvelisib, Positron Emission Tomography, Survey Administration
Procedure · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced May 21, 2026, 5:00 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
T-cell Lymphoma, NK-Cell Lymphoma, T-cell Prolymphocytic Leukemia, T-cell Large Granular Lymphocytic Leukemia, Chronic Lymphoproliferative Disorder of NK Cells, Aggressive NK-cell Leukemia, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Adult T-cell Leukemia/Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Enteropathy-associated T-cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Hepatosplenic T-cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Follicular T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Breast Implant-Associated Anaplastic Large Cell Lymphoma
Interventions
Optional Blood Sample and Nail Sample
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
26
States / cities
Duarte, California • San Diego, California • San Francisco, California + 20 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 5:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Hepatosplenic T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Stage II Angioimmunoblastic T-cell Lymphoma, Stage II Enteropathy-Associated T-Cell Lymphoma, Stage III Angioimmunoblastic T-cell Lymphoma, Stage III Enteropathy-Associated T-Cell Lymphoma, Stage IV Angioimmunoblastic T-cell Lymphoma, Stage IV Enteropathy-Associated T-Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide, Laboratory Biomarker Analysis, Lenalidomide, Peripheral Blood Stem Cell Transplantation, Prednisone, Vincristine Sulfate
Procedure · Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
8
States / cities
Duarte, California • Palo Alto, California • Aurora, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced May 21, 2026, 5:00 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Sezary Syndrome, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Interventions
Durvalumab, Laboratory Biomarker Analysis, Lenalidomide
Biological · Other · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
4
States / cities
Duarte, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced May 21, 2026, 5:00 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
B-cell Follicular Lymphoma, B-cell Marginal Zone Lymphoma, Diffuse Large B-cell Lymphoma, B-cell Mantle Cell Lymphoma, B-cell Small Lymphocytic Lymphoma, B-Cell Chronic Lymphocytic Leukemia, Multiple Myeloma, Waldenstrom's Macroglobulinemia, Noncutaneous Peripheral T-cell Lymphoma Not Otherwise Specified, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Enteropathy Associated T-cell Lymphoma, NK Lymphoma
Interventions
Alisertib
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
10
States / cities
Scottsdale, Arizona • Lexington, Kentucky • Baltimore, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated May 30, 2019 · Synced May 21, 2026, 5:00 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Mature T- Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions
Pembrolizumab, Pralatrexate
Biological · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
3
States / cities
Duarte, California • Atlanta, Georgia • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced May 21, 2026, 5:00 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Classic Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine, Fludarabine Phosphate, Genetically Engineered Lymphocyte Therapy
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years to 75 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced May 21, 2026, 5:00 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Anaplastic Large Cell Lymphoma, Mycosis Fungoides, Relapsed Anaplastic Large Cell Lymphoma, Relapsed Mycosis Fungoides
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Single Photon Emission Computed Tomography, Cemiplimab, Ipilimumab
Procedure · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2032
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 21, 2026, 5:00 PM EDT
Suspended Phase 2 Interventional
View directory record Official record
Conditions
Angioimmunoblastic T-cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Follicular T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Etoposide, Duvelisib, Oral azacitidine
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
86
States / cities
Little Rock, Arkansas • Duarte, California • La Jolla, California + 66 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced May 21, 2026, 5:00 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Carboplatin, Etoposide, Ifosfamide, Romidepsin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2018 · Synced May 21, 2026, 5:00 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Interventions
Pembrolizumab, Romidepsin
Biological · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced May 21, 2026, 5:00 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Follicular T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma
Interventions
Brentuximab Vedotin, Pembrolizumab
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 9, 2023 · Synced May 21, 2026, 5:00 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Adult Acute Myeloid Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mycosis Fungoides, Recurrent Plasma Cell Myeloma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Acute Myeloid Leukemia, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Plasma Cell Myeloma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma
Interventions
Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Positron Emission Tomography, Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter, Single Photon Emission Computed Tomography, Cemiplimab, Ruxolitinib, ipilimumab, Nivolumab, Multigated Acquisition Scan, Echocardiography Test, Bone Marrow Aspiration
Procedure · Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2032
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 21, 2026, 5:00 PM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive, Angioimmunoblastic T-Cell Lymphoma, Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Brentuximab Vedotin, Cyclophosphamide, Doxorubicin, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Laboratory Biomarker Analysis, Prednisone
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
4
States / cities
Duarte, California • Hackensack, New Jersey • Columbus, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2025 · Synced May 21, 2026, 5:00 PM EDT
Recruiting Phase 3 Interventional
View directory record Official record
Conditions
Anaplastic Large Cell Lymphoma, ALK-Negative, Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Best Practice, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, High Dose Chemotherapy, Leukapheresis, Positron Emission Tomography, Stem Cell Mobilization Therapy
Procedure · Other · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years to 75 Years
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
158
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 117 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 21, 2026, 5:00 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Low Grade B-cell Lymphoma, Not Otherwise Specified, Diffuse Large B-cell Lymphoma, Peripheral T-cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Anaplastic Large-cell Lymphoma
Interventions
Clofarabine
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2023 · Synced May 21, 2026, 5:00 PM EDT
Not yet recruiting Phase 1 Interventional
View directory record Official record
Conditions
Follicular Helper T-Cell Lymphoma, Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Follicular Helper T-Cell Lymphoma, Follicular-Type, Follicular Helper T-Cell Lymphoma, Not Otherwise Specified, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography Test, FDG-Positron Emission Tomography, Filgrastim, Fludeoxyglucose F-18, Multigated Acquisition Scan, Pegfilgrastim, Prednisone, Questionnaire Administration, Ruxolitinib Phosphate, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced May 21, 2026, 5:00 PM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelofibrosis, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Erdheim-Chester Disease, Refractory Follicular Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoplasmacytic Lymphoma, Refractory Myelodysplastic Syndrome, Refractory Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Refractory Waldenstrom Macroglobulinemia, Rosai-Dorfman-Destombes Disease, Primary Central Nervous System Lymphoma, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Erdheim-Chester Disease, Recurrent Fibroblastic Reticular Cell Sarcoma, Recurrent Histiocytic Sarcoma, Recurrent Interdigitating Dendritic Cell Sarcoma, Recurrent Rosai-Dorfman-Destombes Disease, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Fibroblastic Reticular Cell Sarcoma, Refractory Histiocytic Sarcoma, Refractory Interdigitating Dendritic Cell Sarcoma, Refractory Rosai-Dorfman-Destombes Disease
Interventions
Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Survey Administration
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced May 21, 2026, 5:00 PM EDT